Insider buying last 90 days
No open-market insider purchases were filed for NUTX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every NUTX insider filing, plotted on the chart in Gekko.Open NUTX in Gekko
NASDAQ: NUTX
Nutex Health (NUTX) Stock Analysis & Forecast
Oct 12 close
$206.15−0.14 (−0.1%)
Gekko Brief
AI summaryOct 12 closeNutex Health shares have been volatile this week, touching a new 52-week high of $224.35 and later $225.25 before pulling back to $206.15. The move follows strong Q2 2026 earnings, with the last call showing H1 2026 revenue of $427.2 million, net income of $112.6 million versus $3.5 million a year earlier, adjusted EBITDA up 2% to $147.5 million, and patient visits up 6.2% to 99,700. Separately, one valuation piece flagged the stock as overvalued against a GF Value estimate of $83.17, while the company also filed a supplement to its proxy statement ahead of its Annual Meeting.
At $206.15, NUTX sits above both its 50-day ($195.56) and 200-day ($148.44) moving averages, with the shorter average above the longer one, reflecting an established uptrend. The GekkoIndex reads 59.1, placing the stock in the Neutral zone. Price remains 11.1% below Gekko Fair Value of $231.91, a gap that has narrowed as shares have climbed off their 52-week low of $83.99.
Over the next 20 trading days, the next earnings date falls outside that window, on 17 November 2026, after the close. No insider, Congress, or unusual options activity appears in the recent windows. Seasonally, the stock has averaged a 20.5% move over the next 20 trading days across 5 years, rising in 4 of them. Analyst sentiment remains fully positive, with all 4 covering firms rating the stock a buy and a consensus target of $288.2, representing 39.8% upside from current levels.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Nutex Health price vs fair value
Close $206.15200-day averageGekko Fair Value $231.91
Nutex Health quick facts
- Market cap
- $1.42B
- P/E ratio
- 8.1
- Forward P/E
- —
- EPS, TTM
- $25.24
- Revenue, TTM
- $846.7M
- Profit margin
- 21.2%
- Dividend yield
- —
- Beta
- 2.00
- Volume
- 122,451 avg 161,160
- 1-year return
- +98.8%
- Typical daily move
- ±5%
- Typical 20-day move
- ±20.8%
- 50-day average
- $195.56
- 200-day average
- $148.44
- Next earnings
- Nov 17 after close
- Shares outstanding
- 6.85M
Nutex Health swing-trade checklist
Nutex Health scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $206.15 is above the 50-day ($195.56) and 200-day ($148.44) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
59.1, Neutral
Reading 59.1 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
11.1% below
Price is 11.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 36 days
Next report Nov 17, 2026, 36 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+20.5% on average
From this point in the calendar, the next 20 trading days averaged +20.5% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Nutex Health stock chart and price history
Nutex Health closed at $206.15 on Oct 12, 2026, +98.8% over the past year, inside a 52-week range of $83.99 to $226.16.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +3.0%
- 3 months
- +15.6%
- 6 months
- +94.0%
- 1 year
- +98.8%
The full NUTX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open NUTX in Gekko
Follow Nutex Health through every session
Put NUTX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track NUTX in GekkoFree for 7 days. No credit card required.
About Nutex Health
Nutex Health operates as a healthcare services business built around technology, working through two main divisions. Its Hospital division creates and runs small-scale hospital facilities, specialty care centers, and outpatient sites, with 21 locations currently in operation across eight states. The company is particularly known for this network of micro-hospitals and related outpatient care settings.
The second division, focused on Population Health Management, builds and oversees provider networks including independent physician associations, and offers management support services covering administrative and operational needs to affiliated hospitals and physician groups. This division also runs a cloud-based technology system that pulls together patient and provider information from various sources and settings, giving a combined view meant to support coordinated care across its network of hospitals and physicians.
Nutex Health is headquartered in Houston, Texas. Its shares trade on the NASDAQ under the ticker NUTX.
- Listed
- NASDAQ
- Sector
- Health services
- Industry
- Medical/Nursing services
- Website
- nutexhealth.com
Nutex Health GekkoIndex: the smart money zone
Nutex Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 59.1, in the Neutral zone, up 8.7 points over five sessions.
59.1Neutral
Up 8.7 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 67 | −2.4% | −4.1% | ||
| Accumulation | 201 | +0.3% | +3.4% | ||
| Neutral (current zone) | 350 | +4.1% | +25.2% | ||
| Distribution | 58 | +9.1% | +8.4% | ||
| Selling | 6 | Too few readings yet | |||
Average NUTX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the NUTX price, zone by zone.Track NUTX in Gekko
Is Nutex Health stock overvalued? Gekko Fair Value
Nutex Health trades 11.1% below Gekko Fair Value of $231.91, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Nutex Health shares are worth, recalculated every trading day.
$231.91
Gekko Fair Value, Oct 10, 2026
11.1% Undervalued
At the end of Aug 2026 the price was 21.2% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open NUTX in Gekko
Nutex Health insider and Congress trading
No open-market insider purchases were filed for Nutex Health, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in NUTX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for NUTX, plotted on the chart in Gekko.Open NUTX in Gekko
Buybacks
Nutex Health has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $18.96M
- As a share of market cap
- 1.34%
From company filings.
Nutex Health earnings: next date and track record
Nutex Health reports on Nov 17, 2026, after the close (36 days away), and beat the EPS estimate in 4 of its last 7 reports.
Next earnings report
Nov 17, 2026
Expected after the close, 36 days away
- EPS estimate
- $5.71
- Revenue estimate
- $215.0M
4 of 7reports beat the EPS estimate
±15.7%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Nutex Health reported H1 2026 total revenue of $427.2M (down 6% YoY due to collection timing), while net income surged to $112.6M vs $3.5M in H1 2025, a 3,100% increase. Adjusted EBITDA rose 2% to $147.5M. Patient visits grew 6.2% to 99,700, with same-hospital visits up 6.3% in Q2. Cash on hand increased to $207.1M with operating cash flow up 40% to $109.7M.
- Guidance
- Management cited revenue stabilization in 2026 vs 2025, ongoing IDR process improvements, and continued volume/acuity growth as tailwinds. No specific numerical revenue or earnings targets were provided in this excerpt.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $9.58 est $5.26 | $210.8M est $215.0M | +3.1% |
| Apr 30, 2026 | $5.74 est $5.56 | $216.5M est $227.8M | +24.6% |
| Mar 5, 2026 | $1.62 est $5.56 | $151.7M est $258.8M | −16.7% |
| Oct 22, 2025 | −$2.95 est −$1.43 | $244.0M est $244.0M | +2.4% |
| Mar 31, 2025 | $11.12 est −$0.12 | $257.6M est $81.13M | +38.2% |
| Nov 8, 2024 | −$0.32 est $0.28 | $78.79M est $73.22M | −3.4% |
| Aug 8, 2024 | −$0.07 est −$0.29 | $76.08M est $68.20M | +29.0% |
| May 8, 2024 | −$0.06 | $67.45M est $67.45M | +8.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Nutex Health stock forecast and analyst price targets
Analysts’ average 12-month price target for Nutex Health is $288.20, +39.8% from the last close, from 4 firms rating the stock in the last 90 days.
$288.20consensus 12-month target, +39.8% from the last close
Now $206.15Avg $288.20
Low $200High $325
Each firm’s latest rating in the last 90 days: 4 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 25 | Freedom Capital Markets | $306 | +48.4% |
| Sep 4 | B. Riley Securities | $325 | +57.7% |
| Aug 11 | Lake Street | $310 | +50.4% |
| Aug 10 | Maxim Group | $200 | −3.0% |
+25.2%average 20-day move after past Neutral readings
+20.5%average move over the next 20 trading days in the last 5 years
±5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Nutex Health seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Nutex Health averaged +20.5% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +11.9% | 5 of 5 |
| Next 10 trading days | +9.6% | 3 of 5 |
| Next 15 trading days | +16.6% | 4 of 5 |
| Next 20 trading days | +20.5% | 4 of 5 |
| Next 30 trading days | +35.5% | 4 of 5 |
For scale, NUTX’s typical 20-trading-day move in either direction is about 20.8%.
Nutex Health market cap and key statistics
Nutex Health’s market cap is $1.42B, with a P/E ratio of 8.1 and revenue of $846.7M over the last twelve months.
Valuation
- Market cap
- $1.42B
- P/E ratio
- 8.1
- EPS, TTM
- $25.24
- Gekko Fair Value
- $231.91
Trading
- Volume
- 122,451
- Avg volume, 20 days
- 161,160
- 52-week high
- $226.16
- 52-week low
- $83.99
- Shares outstanding
- 6.85M
Financials
- Revenue, TTM
- $846.7M
- Profit margin
- 21.2%
- Return on equity
- 64.6%
- Quarterly earnings growth, YoY
- +95.9%
Risk and income
- Beta
- 2.00
- Typical daily move
- ±5%
- Typical 20-day move
- ±20.8%
Nutex Health stock news this week
Coverage of Nutex Health this week reads neutral: 1 positive, 1 neutral and 1 negative headlines.
- A Look at Nutex Health Inc (NUTX) After 3.8% Decline -- GF Value $83.17 vs Price $205.01GuruFocus, Oct 9
- NUTEX HEALTH ANNOUNCES THAT IT HAS FILED A SUPPLEMENT TO ITS PROXY STATEMENTLelezard, Oct 7
- Nutex Health (NASDAQ:NUTX) Reaches New 12-Month High – Still a Buy?Defense World, Oct 7
- Nutex Health (NASDAQ:NUTX) versus HCA Healthcare (NYSE:HCA) Head-To-Head SurveyDefense World, Oct 6
- Nutex Health stock hits 52-week high at 224.35 USDInvesting.com, Oct 5
Nutex Health peers
Nutex Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Neutral | 2.5% below |
| GHGuardant Health | Accumulation | 10.0% below |
| SOLVSolventum | Accumulation | 20.5% below |
| BTSGBrightSpring Health Services | Neutral | 2.8% above |
| EHCEncompass Health | Neutral | 7.3% above |
| DVADaVita | Neutral | 14.6% below |
A peer links to its own page where one exists.
Nutex Health stock FAQ
What is Nutex Health’s market cap?
Nutex Health’s market cap is $1.42B at the Oct 12, 2026 close of $206.15, with 6.85M shares outstanding. The shares trade on a P/E ratio of 8.1.
What is the Nutex Health stock forecast?
The consensus analyst 12-month price target for Nutex Health is $288.20, +39.8% from the last close. Of the 4 firms that rated the stock in the last 90 days, 4 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Nutex Health stock overvalued or undervalued?
On Gekko’s estimate Nutex Health is undervalued: the Oct 12, 2026 close of $206.15 is 11.1% below Gekko Fair Value of $231.91. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Nutex Health report earnings next?
Nutex Health is expected to report on Nov 17, 2026, after the market closes (36 days away). Analysts expect earnings of $5.71 per share on revenue of $215.0M. Nutex Health beat the earnings estimate in 4 of its last 7 reports, moving 15.7% on average across the report.
What is Nutex Health’s 52-week high and low?
Nutex Health’s 52-week high is $226.16 and its 52-week low is $83.99; it closed at $206.15 on Oct 12, 2026, +98.8% over the past year. Over the last five years the shares peaked at $7,920.00 on Apr 4, 2022.
Is Nutex Health stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (trend, fair value, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Nutex Health the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.